Findings confirm link between methimazole and risk for acute pancreatitis
CHICAGO – However, there is no evidence of a cumulative dose effect.
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
From the Society
Glycemic Control eQUIPS yields success at Dignity Health Sequoia Hospital
The tools available in the GC eQUIPS program are powerful for data analysis and benchmarking.
New model for CKD risk draws on clinical, demographic factors
The equation has demonstrated high discrimination and variable calibration across a range of populations.
Dapagliflozin approved for reducing HF hospitalization in diabetes
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
Certain diabetes drugs may thwart dementia
COPENHAGEN – Intriguing findings from a Danish national registry study.
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.
Machine learning–derived risk score predicts heart failure risk in diabetes patients
Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%.
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug
Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD
Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy.